✨ Free AI Report
ORIC Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research ORIC Pharmaceuticals, Inc.
Company Research

ORIC Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of therapies to counter the resistance mechanisms in cancers. The company focuses on developing novel oncolog...

Analyst-debate audio for ORIC Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for ORIC Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
5/ 10Mixed

Cyborg Score thesis

Early-stage oncology play with compelling resistance-targeting approach, but dependent on clinical trial success and future...

Read the full analyst-debate transcript →
Industry Oncology Drugs
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest ORIC Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

ORIC Pharmaceuticals, Inc. Overview

Pro stress-test →

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of therapies to counter the resistance mechanisms in cancers. The company focuses on developing novel oncology treatments that address key therapeutic resistance pathways across multiple cancer indications.

Strategic Profile

Pro stress-test →

ORIC is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Lead candidates include enozertinib (ORIC-114) and rinzimetostat (ORIC-944) in clinical development.

Competitive Landscape

Pro stress-test →

ORIC competes in the precision oncology space against larger pharma programs and specialized biotech companies developing targeted cancer therapies. Competitors focus on similar resistance mechanisms and EGFR/HER2-targeted approaches in non-small cell lung cancer and other indications.

Industry Context

ORIC Pharmaceuticals, Inc. operates in Oncology Drugs.

Key facts

Founded: 2014 · Headquarters: South San Francisco, US · Employees: N/A · Revenue: N/A · Market cap: N/A

What the analysts stress-tested

The top findings that survived the multi-agent debate for ORIC Pharmaceuticals, Inc..

  • Pipeline addresses three strategic oncology areas: hormone-dependent cancers, precision oncology, and key tumor dependencies.
  • Lead program enozertinib (ORIC-114) is a brain penetrant EGFR/HER2 exon 20 inhibitor in Phase 1b development.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • May 2026Positive analyst sentiment with Buy ratings from Piper Sandler, Guggenheim, and Wells Fargo
  • January 2024Closed $125 million Series C private placement financing
  • +1 moreTrack every material event for ORIC Pharmaceuticals, Inc. as it happens. Explore monitoring →
Get alerted when ORIC Pharmaceuticals, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

TagrissoEGFR mutation-targeted lung cancer therapy→ExkivityEGFR exon 20 insertion inhibitor for lung cancer→Loxo Oncology programsPrecision oncology targeting TRK and other mutations→

Compare ORIC Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

ORIC Pharmaceuticals, Inc. operates in Oncology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Oncology Drugs research →
NEW · MCP server

Ask your AI assistant about ORIC Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare ORIC Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did ORIC Pharmaceuticals, Inc. do this quarter?”
“Is ORIC Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does ORIC Pharmaceuticals, Inc. do?+
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of therapies to counter the resistance mechanisms in cancers. The company focuses on developing novel oncolog...
What is ORIC Pharmaceuticals, Inc.'s Cyborg Score?+
ORIC Pharmaceuticals, Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are ORIC Pharmaceuticals, Inc.'s main competitors?+
Named competitors include Tagrisso, Exkivity, Loxo Oncology programs. The full competitive landscape is in the AskCyborg report.
How can I get the full ORIC Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the ORIC Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track ORIC Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.